Last edition
News about "Kaivan Khavandi"
GSK and Empirico Sign Licensing Deal for Respiratory Oligonucleotide
Oligonucleotide therapies, including siRNA, offer the potential to modulate gene expression and target diseases beyond the reach of traditional drugs. EMP-012 adds to GSK’s growing oligonucleotide pipeline across respiratory, immunology and inflammation, and infectious disease portfolios.
Kaivan Khavandi | 29/10/2025 | By Dineshwori
GSK Completes Acquisition of Efimosfermin from Boston Pharmaceuticals for USD 2 Billion
GSK has completed its acquisition of efimosfermin alfa, a Phase III-ready investigational therapy for serious liver diseases, from Boston Pharmaceuticals in a deal worth up to USD 2 billion.
Kaivan Khavandi | 09/07/2025 | By Mrinmoy Dey | 125
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy